COMP <GO>
CDNA vs JNJ // NET PROFIT MARGIN
CareDx Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CDNA 5
— JNJ 8
▲ NET PROFIT MARGIN LEADER: JNJ
LAST: $87.41 (+22.22%) • MKT CAP: $3.70B
net-margins
-5.60%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
net-margins
28.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CDNA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CDNA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -8.20% | 25.50% | -33.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.67% | 2.97% | -2.30 | JNJ | /fcf-yield <GO> |
| Operating Margin | -8.10% | 34.70% | -42.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -5.60% | 28.50% | -34.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 13.80% | 6.00% | +7.80 | CDNA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.22 | 5.59 | +13.63 | CDNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | CDNA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 81.9 | 60.4 | +21.55 | CDNA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.08 | -0.02 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 23.0x | -2.00 | CDNA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.70B | $662.49B | -$658.79B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CDNA REV | JNJ REV | CDNA GROSS % | JNJ GROSS % | CDNA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $379.8M | $94.19B | 44.0% | 67.9% | $24.9M | $19.70B |
| FY 2024 | $333.8M | $88.82B | 44.0% | 69.1% | $23.0M | $19.84B |
| FY 2023 | $280.3M | $85.16B | 44.0% | 44.0% | -$31.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CDNA // BETA 1.06
JNJ // BETA 1.08